When was Ashibio founded?

Ashibio was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is Ashibio located?

Ashibio is headquartered in Redwood City, United States.

Is Ashibio a funded company?

Ashibio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jun 20, 2024.

When was the latest funding round of Ashibio?

Ashibio's latest funding was a $***** Series A round on Jun 20, 2024, with participation from 3 investors. Its primary sector is Orthopedics. In United States, the Orthopedics sector has seen $2.38B in funding in 2026 to date.

Where does Ashibio rank among its competitors?

Ashibio ranks 13th amongst 98 active competitors, of which 22 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was BioStem Technologies, which secured $2.5M in May, 2026.

Who are the top competitors of Ashibio?

Ashibio's top competitors include argenx, Vor Biopharma and Radius Health. Among them, BioStem Technologies secured the most recent funding round in May, 2026.

Ashibio - 2026 Company Profile, Funding & Competitors

Company Details

Developer of novel therapies for patients with rare bone and connective tissue disorders. It offer therapeutics that aim to prevent the onset of symptoms or delay their progression.

Website: ashibio.com
Email ID: *****@ashibio.com

Key Metrics

Founded Year

2021

Location

Redwood City, United States

Stage

Series A

Total Funding

$40M in 1 round

Latest Funding Round

Series A, Jun 20, 2024, $*****

Investors

MPM BioImpact & 2 more

Ranked

13^th among 98 active competitors

Similar Companies

argenx & 118 more

View Ashibio's full profile

Ashibio has raised a total funding of $40M over 1 round. Its latest funding round was a Series A round on Jun 20, 2024 for $*****. 3 investors participated in its latest round. Ashibio has 3 institutional investors.

Here is the list of recent funding rounds of Ashibio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 20, 2024	1852898	Series A	6175842	2245113	7928707	4384899

Access funding benchmarks and valuations. Sign up today!

View details of Ashibio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ashibio include argenx, Vor Biopharma and Radius Health. Here is the list of Top 10 competitors of Ashibio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
3rd	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
4th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Atlas Venture, Avoro Capital & 4 others	61/100
5th	Quince Therapeutics 2012, San Francisco (United States), Public	Developer of therapeutics for orthopedic diseases	$108M	Pfizer Venture Investments, Balyasny Asset Management ... & 26 others	60/100
6th	Angitia 2018, Woodland Hills (United States), Series D	Developer of drugs for muscle, bone, and joint diseases	$406M	Morningside, Bain Capital Life Sciences & 28 others	58/100
7th	Valitor 2010, Berkeley (United States), Series B	Developer of therapeutic proteins for multiple disease conditions	$38.2M	Morningside, ShangPharma Innovation & 9 others	55/100
8th	Ingeneron 2005, Houston (United States), Series D	Developer of cell-separation technology for regenerative medicine	$51.4M	Sanford Health, German Accelerator	53/100
9th	BioStem Technologies 2006, Pompano Beach (United States), Public	Provider of placental-based amniotic tissue products	-	-	51/100
10th	Osteal Therapeutics 2013, San Clemente (United States), Series D	Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections	$126M	Johnson & Johnson Innovation – JJDC, Huimei Capital ... & 7 others	51/100
13th	Ashibio 2021, Redwood City (United States), Series A	Developer of novel therapies for patients with rare bone and connective tissue disorders.	$40M	Agent Capital, MPM BioImpact & 1 others	49/100